Five-year survival with tebentafusp in metastatic uveal melanoma.
Ann OncolMay 19, 2026 (epub)
Clinical ResearchOncology (Medical)
S Piperno-Neumann, P Rutkowski, J C Hassel et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3 randomized controlled trial evaluated the long-term survival of HLA-A∗02:01-positive patients with metastatic uveal melanoma treated with tebentafusp compared to investigator's choice therapies. The final analysis showed a median overall survival of 21.6 months for tebentafusp versus 16.9 months for controls, with 5-year survival rates of 16% and 8%, respectively.
Key findings
- Median overall survival was 21.6 months for tebentafusp versus 16.9 months for controls.
- Five-year overall survival rates were 16% for tebentafusp and 8% for the control group.
- Tebentafusp improved survival in poor-prognosis groups, including those with large tumors.
- Patients with undetectable ctDNA at baseline had longer overall survival.
Why it matters
The findings underscore the effectiveness of tebentafusp as a first-line treatment for metastatic uveal melanoma, particularly in patients with poor prognostic factors, highlighting its potential to improve long-term outcomes.